Oruka Therapeutics (NASDAQ:ORKA) & Myriad Genetics (NASDAQ:MYGN) Critical Review

Myriad Genetics (NASDAQ:MYGN) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends and earnings.

Earnings and Valuation

This table compares Myriad Genetics and Oruka Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$823.60 million	1.64	-$263.30 million	($1.30)	-11.41
Oruka Therapeutics	N/A	N/A	-$5.34 million	($6.26)	-2.51

Oruka Therapeutics has lower revenue, but higher earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 2.1% of Myriad Genetics shares are owned by insiders. Comparatively, 22.7% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Myriad Genetics has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.

Profitability

This table compares Myriad Genetics and Oruka Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-14.09%	-4.51%	-3.07%
Oruka Therapeutics	N/A	-24.96%	-21.22%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Myriad Genetics and Oruka Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	3	6	3	0	2.00
Oruka Therapeutics	0	0	7	1	3.13

Myriad Genetics currently has a consensus target price of $24.27, indicating a potential upside of 63.67%. Oruka Therapeutics has a consensus target price of $43.17, indicating a potential upside of 174.60%. Given Oruka Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Oruka Therapeutics is more favorable than Myriad Genetics.

Summary

Oruka Therapeutics beats Myriad Genetics on 8 of the 14 factors compared between the two stocks.

About Myriad Genetics

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

About Oruka Therapeutics

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.